{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:41Z","timestamp":1790144201951,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["95653117\/95653118"],"award-info":[{"award-number":["95653117\/95653118"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C19942\/A28832"],"award-info":[{"award-number":["C19942\/A28832"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTRQQR-2021\\100010"],"award-info":[{"award-number":["CTRQQR-2021\\100010"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health Research (NIHR) Manchester Biomedical Research Centre"},{"name":"Cancer Research UK (CRUK) Leeds Radiotherapy Research Centre","award":["C19942\/A28832"],"award-info":[{"award-number":["C19942\/A28832"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To investigate the value of combining MRI radiomic and hypoxia-associated gene signature information with clinical data for predicting biochemical recurrence-free survival (BCRFS) after radiotherapy for prostate cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with biopsy-proven prostate cancer, hypoxia-associated gene signature scores and pre-treatment MRI who received radiotherapy between 01\/12\/2007 and 31\/08\/2013 at two cancer centres were included in this retrospective cohort analysis. Prostate segmentation was performed on axial T2-weighted sequences using RayStation (v9.1). Histogram standardisation was applied prior to radiomic feature (RF) extraction. PyRadiomics (v3.0.1) was used to extract RFs for analysis. Four multivariable Cox proportional hazards BCRFS prediction models using clinical information alone and in combination with RFs and\/or hypoxia scores were evaluated using concordance index (C-index) [confidence intervals (CI)]. Akaike Information Criterion (AIC) was used to assess model fit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>178 patients were included. The clinical-only model performance C-index score was 0.69 [0.64\u20130.7]. The combined clinical-radiomics model (C-index 0.70[0.66\u20130.73]) and clinical-radiomics-hypoxia model (C-index 0.70[0.65\u20130.73]) both had higher model performance. The clinical-hypoxia model (C-index 0.68 [0.63\u20130.7) had lower model performance. Based on AIC, addition of RFs to clinical variables alone improved model performance (<jats:italic>p<\/jats:italic>\u2009=\u20090.027), whereas adding hypoxia gene signature scores did not (<jats:italic>p<\/jats:italic>\u2009=\u20090.625). The selected features of the combined clinical-radiomics model included age, ISUP grade, tumour stage, and wavelet-derived grey level co-occurrence matrix (GLCM) RFs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Adding pre-treatment prostate MRI-derived radiomic features to a clinical model improves accuracy of predicting BCRFS after prostate radiotherapy, however addition of hypoxia gene signatures does not improve model accuracy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11547-025-02037-4","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:06:59Z","timestamp":1751436419000},"page":"1139-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combining MRI radiomics, hypoxia gene signature score and clinical variables for prediction of biochemical recurrence-free survival after radiotherapy in prostate cancer"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5325-3739","authenticated-orcid":false,"given":"Jim","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Frood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"McWilliam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Shortall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Reaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Swinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Scarsbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"2037_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J et al (2024) The lancet commission on prostate cancer: planning for the surge in cases. The Lancet 403:1683\u20131722","journal-title":"The Lancet"},{"key":"2037_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"},{"key":"2037_CR3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.juro.2015.06.100","volume":"194","author":"ZS Zumsteg","year":"2015","unstructured":"Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, McBride S, Yamada Y, Zelefsky MJ (2015) Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J Urol 194:1624\u20131630","journal-title":"J Urol"},{"key":"2037_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102206","volume":"98","author":"BA Jereczek-Fossa","year":"2021","unstructured":"Jereczek-Fossa BA, Marvaso G, Zaffaroni M et al (2021) Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi consensus. Cancer Treat Rev 98:102206","journal-title":"Cancer Treat Rev"},{"key":"2037_CR5","first-page":"14","volume":"11","author":"CJ Paller","year":"2013","unstructured":"Paller CJ, Antonarakis ES (2013) Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 11:14\u201323","journal-title":"Clin Adv Hematol Oncol"},{"key":"2037_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ et al (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:479\u2013505","journal-title":"J Natl Compr Canc Netw"},{"key":"2037_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","volume":"36","author":"DE Spratt","year":"2018","unstructured":"Spratt DE, Zhang J, Santiago-Jim\u00e9nez M et al (2018) Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol 36:581\u2013590","journal-title":"J Clin Oncol"},{"key":"2037_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL (2002) Hypoxia\u2013a key regulatory factor in tumour growth. Nat Rev Cancer 2:38\u201347","journal-title":"Nat Rev Cancer"},{"key":"2037_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","volume":"15","author":"E Lalonde","year":"2014","unstructured":"Lalonde E, Ishkanian AS, Sykes J et al (2014) Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 15:1521\u20131532","journal-title":"Lancet Oncol"},{"key":"2037_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-11-2711","volume":"18","author":"M Milosevic","year":"2012","unstructured":"Milosevic M, Warde P, M\u00e9nard C et al (2012) Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 18:2108\u20132114","journal-title":"Clin Cancer Res"},{"key":"2037_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ebiom.2018.04.019","volume":"31","author":"L Yang","year":"2018","unstructured":"Yang L, Roberts D, Takhar M et al (2018) Development and validation of a 28-gene hypoxia-related prognostic signature for localized prostate cancer. EBioMedicine 31:182\u2013189","journal-title":"EBioMedicine"},{"key":"2037_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/bjc.2014.604","volume":"112","author":"HB Ragnum","year":"2015","unstructured":"Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H (2015) The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br J Cancer 112:382\u2013390","journal-title":"Br J Cancer"},{"key":"2037_CR13","first-page":"4509","volume":"56","author":"M Hockel","year":"1996","unstructured":"Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509\u20134515","journal-title":"Cancer Res"},{"key":"2037_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10334-022-01006-6","volume":"35","author":"MC Fernandes","year":"2022","unstructured":"Fernandes MC, Yildirim O, Woo S, Vargas HA, Hricak H (2022) The role of MRI in prostate cancer: current and future directions. Magn Reson Mater Phys, Biol Med 35:503\u2013521","journal-title":"Magn Reson Mater Phys, Biol Med"},{"key":"2037_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"4","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 4:749\u2013762","journal-title":"Nat Rev Clin Oncol"},{"key":"2037_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.974257","author":"Y Jia","year":"2022","unstructured":"Jia Y, Quan S, Ren J, Wu H, Liu A, Gao Y, Hao F, Yang Z, Zhang T, Hu H (2022) MRI radiomics predicts progression-free survival in prostate cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.974257","journal-title":"Front Oncol"},{"key":"2037_CR17","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210838","author":"R Zheng","year":"2022","unstructured":"Zheng R, Cai M, Lan L, Huang XW, Yang YJ, Powell M, Lin F (2022) An MRI-based radiomics signature and clinical characteristics for survival prediction in early-stage cervical cancer. Br J Radiol. https:\/\/doi.org\/10.1259\/bjr.20210838","journal-title":"Br J Radiol"},{"key":"2037_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s11060-021-03939-9","volume":"156","author":"BJ Geraghty","year":"2022","unstructured":"Geraghty BJ, Dasgupta A, Sandhu M et al (2022) Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes. J Neurooncol 156:579\u2013588","journal-title":"J Neurooncol"},{"key":"2037_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.euros.2020.06.006","volume":"20","author":"JM Norris","year":"2020","unstructured":"Norris JM, Simpson BS, Parry MA et al (2020) Genetic landscape of prostate cancer conspicuity on multiparametric magnetic resonance imaging: a systematic review and bioinformatic analysis. Eur Urol Open Sci 20:37\u201347","journal-title":"Eur Urol Open Sci"},{"key":"2037_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.radonc.2020.10.016","volume":"153","author":"S Sanduleanu","year":"2020","unstructured":"Sanduleanu S, Jochems A, Upadhaya T et al (2020) Non-invasive imaging prediction of tumor hypoxia: a novel developed and externally validated CT and FDG-PET-based radiomic signatures. Radiother Oncol 153:97\u2013105","journal-title":"Radiother Oncol"},{"key":"2037_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102841","volume":"57","author":"CS Fjeldbo","year":"2020","unstructured":"Fjeldbo CS, Hompland T, Hillestad T, Aarnes E-K, G\u00fcnther C-C, Kristensen GB, Malinen E, Lyng H (2020) Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity. EBioMedicine 57:102841","journal-title":"EBioMedicine"},{"key":"2037_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.21873\/anticanres.16170","volume":"43","author":"M Leech","year":"2023","unstructured":"Leech M, Leijenaar RTH, Hompland T, Gaffney J, Lyng H, Marignol L (2023) Exploring hypoxia in prostate cancer with T2-weighted magnetic resonance imaging radiomics and pimonidazole scoring. Anticancer Res 43:351\u2013357","journal-title":"Anticancer Res"},{"key":"2037_CR23","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.240300","author":"AS Tejani","year":"2024","unstructured":"Tejani AS, Klontzas ME, Gatti AA et al (2024) Checklist for artificial intelligence in medical imaging (CLAIM): 2024 update. Radiol Artif Intell. https:\/\/doi.org\/10.1148\/ryai.240300","journal-title":"Radiol Artif Intell"},{"key":"2037_CR24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","volume":"51","author":"V Bhandari","year":"2019","unstructured":"Bhandari V, Hoey C, Liu LY et al (2019) Molecular landmarks of tumor hypoxia across cancer types. Nat Genet 51:308\u2013318","journal-title":"Nat Genet"},{"key":"2037_CR25","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin J-C, Pieper S, Aerts HJWL (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77:e104\u2013e107","journal-title":"Cancer Res"},{"key":"2037_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1109\/42.836373","volume":"19","author":"LG Nyul","year":"2000","unstructured":"Nyul LG, Udupa JK, Zhang X (2000) New variants of a method of MRI scale standardization. IEEE Trans Med Imaging 19:143\u2013150","journal-title":"IEEE Trans Med Imaging"},{"key":"2037_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295:328\u2013338","journal-title":"Radiology"},{"key":"2037_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuroimage.2017.11.024","volume":"167","author":"J-P Fortin","year":"2018","unstructured":"Fortin J-P, Cullen N, Sheline YI et al (2018) Harmonization of cortical thickness measurements across scanners and sites. Neuroimage 167:104\u2013120","journal-title":"Neuroimage"},{"key":"2037_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8:118\u2013127","journal-title":"Biostatistics"},{"key":"2037_CR30","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/abfa34","volume":"66","author":"A Davey","year":"2021","unstructured":"Davey A, van Herk M, Faivre-Finn C, Brown S, McWilliam A (2021) Optimising use of 4D-CT phase information for radiomics analysis in lung cancer patients treated with stereotactic body radiotherapy. Phys Med Biol 66:115012","journal-title":"Phys Med Biol"},{"key":"2037_CR31","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/bioinformatics\/btt383","volume":"29","author":"N De Jay","year":"2013","unstructured":"De Jay N, Papillon-Cavanagh S, Olsen C, El-Hachem N, Bontempi G, Haibe-Kains B (2013) mRMRe: an R package for parallelized mRMR ensemble feature selection. Bioinformatics 29:2365\u20132368","journal-title":"Bioinformatics"},{"key":"2037_CR32","first-page":"62","volume":"26","author":"A Rabasco Meneghetti","year":"2021","unstructured":"Rabasco Meneghetti A, Zwanenburg A, Leger S et al (2021) Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. Clin Transl Radiat Oncol 26:62\u201370","journal-title":"Clin Transl Radiat Oncol"},{"key":"2037_CR33","volume-title":"Information theory and an extension of the maximum likelihood principle","author":"A Hirotogu","year":"1998","unstructured":"Hirotogu A (1998) Information theory and an extension of the maximum likelihood principle. Springer New York, New York"},{"key":"2037_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0049124104268644","volume":"33","author":"KP Burnham","year":"2004","unstructured":"Burnham KP, Anderson DR (2004) Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res 33:261\u2013304","journal-title":"Sociol Methods Res"},{"key":"2037_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217702","volume":"14","author":"J Toivonen","year":"2019","unstructured":"Toivonen J, Montoya Perez I, Movahedi P et al (2019) Radiomics and machine learning of multisequence multiparametric prostate MRI: towards improved non-invasive prostate cancer characterization. PLoS ONE 14:e0217702","journal-title":"PLoS ONE"},{"key":"2037_CR36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.21037\/qims.2019.12.06","volume":"10","author":"M Li","year":"2020","unstructured":"Li M, Chen T, Zhao W, Wei C, Li X, Duan S, Ji L, Lu Z, Shen J (2020) Radiomics prediction model for the improved diagnosis of clinically significant prostate cancer on biparametric MRI. Quant Imaging Med Surg 10:368\u2013379","journal-title":"Quant Imaging Med Surg"},{"key":"2037_CR37","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1007\/s00330-015-3701-8","volume":"25","author":"A Wibmer","year":"2015","unstructured":"Wibmer A, Hricak H, Gondo T et al (2015) Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol 25:2840\u20132850","journal-title":"Eur Radiol"},{"key":"2037_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00630","author":"A Chaddad","year":"2018","unstructured":"Chaddad A, Niazi T, Probst S, Bladou F, Anidjar M, Bahoric B (2018) Predicting gleason score of prostate cancer patients using radiomic analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2018.00630","journal-title":"Front Oncol"},{"key":"2037_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jmri.25335","volume":"45","author":"K Gnep","year":"2017","unstructured":"Gnep K, Fargeas A, Guti\u00e9rrez-Carvajal RE et al (2017) Haralick textural features on T2 -weighted MRI are associated with biochemical recurrence following radiotherapy for peripheral zone prostate cancer. J Magn Reson Imaging 45:103\u2013117","journal-title":"J Magn Reson Imaging"},{"key":"2037_CR40","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ijrobp.2007.01.018","volume":"68","author":"PJ Hoskin","year":"2007","unstructured":"Hoskin PJ, Carnell DM, Taylor NJ et al (2007) Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 68:1065\u20131071","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2037_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.radonc.2011.12.007","volume":"103","author":"G Groenendaal","year":"2012","unstructured":"Groenendaal G, van Vulpen M, Pereboom SR, Poelma-Tap D, Korporaal JG, Monninkhof E, van der Heide UA (2012) The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy. Radiother Oncol 103:233\u2013238","journal-title":"Radiother Oncol"},{"key":"2037_CR42","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-17-3806","volume":"78","author":"T Hompland","year":"2018","unstructured":"Hompland T, Hole KH, Ragnum HB, Aarnes E-K, Vlatkovic L, Lie AK, Patzke S, Brennhovd B, Seierstad T, Lyng H (2018) Combined MR imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness in prostate cancer patients. Cancer Res 78:4774\u20134785","journal-title":"Cancer Res"},{"key":"2037_CR43","unstructured":"Reardon MD, Bibby BAS, Thiruthaneeswaran N, Pereira R, Mistry H, More E, Song JM, Kim SD, Kim JH, Kim MJ, Kang DH, Seo JB, et al (2024) Hypoxia-associated gene signatures are not prognostic in high-risk localised prostate cancers undergoing androgen deprivation therapy with radiotherapy. Int J Radiat Oncol Biol Phys. 2024 October (In Press)."},{"key":"2037_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00157","author":"A Offermann","year":"2017","unstructured":"Offermann A, Hohensteiner S, Kuempers C et al (2017) Prognostic value of the new prostate cancer international society of urological pathology grade groups. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2017.00157","journal-title":"Front Med (Lausanne)"},{"key":"2037_CR45","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ejso.2017.12.003","volume":"44","author":"C De Nunzio","year":"2018","unstructured":"De Nunzio C, Pastore AL, Lombardo R et al (2018) The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. Eur J Surg Oncol 44:835\u2013839","journal-title":"Eur J Surg Oncol"},{"key":"2037_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001261","volume":"2","author":"S von Ahlfen","year":"2007","unstructured":"von Ahlfen S, Missel A, Bendrat K, Schlumpberger M (2007) Determinants of RNA quality from FFPE samples. PLoS ONE 2:e1261","journal-title":"PLoS ONE"},{"key":"2037_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1687-6180-2012-40","volume":"2012","author":"Y Wang","year":"2012","unstructured":"Wang Y, Che X, Ma S (2012) Nonlinear filtering based on 3D wavelet transform for MRI denoising. EURASIP J Adv Signal Process 2012:40","journal-title":"EURASIP J Adv Signal Process"},{"key":"2037_CR48","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s11547-023-01644-3","volume":"128","author":"J Zhong","year":"2023","unstructured":"Zhong J, Frood R, McWilliam A et al (2023) Prediction of prostate tumour hypoxia using pre-treatment MRI-derived radiomics: preliminary findings. Radiol Med 128:765\u2013774","journal-title":"Radiol Med"},{"key":"2037_CR49","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.3390\/jcm12072605","volume":"12","author":"CN Ogbonnaya","year":"2023","unstructured":"Ogbonnaya CN, Alsaedi BSO, Alhussaini AJ, Hislop R, Pratt N, Nabi G (2023) Radiogenomics reveals correlation between quantitative texture radiomic features of biparametric MRI and hypoxia-related gene expression in men with localised prostate cancer. J Clin Med 12:2605","journal-title":"J Clin Med"},{"key":"2037_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417\u2013428","journal-title":"N Engl J Med"},{"key":"2037_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.696364","author":"H Xia","year":"2021","unstructured":"Xia H, Wang J, Guo X, Lv Z, Liu J, Yan Q, Liu M, Wang J (2021) Identification of a hypoxia-related gene signature for predicting systemic metastasis in prostate cancer. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2021.696364","journal-title":"Front Cell Dev Biol"},{"key":"2037_CR52","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ijrobp.2018.04.044","volume":"101","author":"SD McGarry","year":"2018","unstructured":"McGarry SD, Hurrell SL, Iczkowski KA et al (2018) Radio-pathomic maps of epithelium and lumen density predict the location of high-grade prostate cancer. Int J Radiat Oncol Biol Phys 101:1179\u20131187","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2037_CR53","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.3390\/cancers13194897","volume":"13","author":"EJ Her","year":"2021","unstructured":"Her EJ, Haworth A, Sun Y, Williams S, Reynolds HM, Kennedy A, Ebert MA (2021) Biologically targeted radiation therapy: incorporating patient-specific hypoxia data derived from quantitative magnetic resonance imaging. Cancers (Basel) 13:4897","journal-title":"Cancers (Basel)"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-02037-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:28:15Z","timestamp":1757204895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-02037-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2037"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-02037-4","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the United Kingdom North West Research Ethics Committee (Validation and qualification of a multiplex hypoxia biomarker for radiotherapy individualisation in prostate cancer study (IRAS 15\/NW\/0559)).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human or animal rights"}}]}}